At-home light-emitting diode (LED) devices are effective for treating acne, according to a research letter published online ...

Sanofi Consumer Healthcare Indias shares finished Thursday 1.42% higher at Rs 4,815 a share, with a market capitalisation of ...

A new analysis provides substantial evidence that paramagnetic rim lesions drive disability in MS and are targetable with a ...

Posters presented at the Association of Cancer Care Centers opening session covered initiatives to boost clinical trial ...

South Africa's Competition Commission is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...

Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...

Sanofi successfully prices EUR 1.5 billion of bond issue Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of ...

Berenberg analyst Luisa Hector raised the firm’s price target on Sanofi (SNY) to EUR 120 from EUR 115 and keeps a Buy rating on the ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

Sanofi SA has described Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of allergy, pain, dermatological and inflammatory disorders.

South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...